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Abstract
Previous studies have shown that inducing autophagy ameliorates early cognitive deficits associated with the build-up of
soluble amyloid-b (Ab). However, the effects of inducing autophagy on plaques and tangles are yet to be determined. While
soluble Ab and tau represent toxic species in Alzheimer’s disease (AD) pathogenesis, there is well documented evidence
that plaques and tangles also are detrimental to normal brain function. Thus, it is critical to assess the effects of inducing
autophagy in an animal model with established plaques and tangles. Here we show that rapamycin, when given
prophylactically to 2-month-old 3xTg-AD mice throughout their life, induces autophagy and significantly reduces plaques,
tangles and cognitive deficits. In contrast, inducing autophagy in 15-month-old 3xTg-AD mice, which have established
plaques and tangles, has no effects on AD-like pathology and cognitive deficits. In conclusion, we show that autophagy
induction via rapamycin may represent a valid therapeutic strategy in AD when administered early in the disease
progression.
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Introduction
Amyloid-b (Ab) plaques and neurofibrillary tangles (NFTs) are
the two neuropathological hallmarks of Alzheimer’s disease (AD
[1]). Tau, a microtubule-binding protein, is the main constituent of
NFTs. In recent years there has been a growing appreciation for a
primary role for the build-up of soluble Ab and tau in the
pathogenesis of AD [2]. As the disease progresses, Ab and tau
aggregate to form plaques and NFTs, which further exacerbate
AD-associated cognitive impairments [2]. Indeed, evidence
showing that Ab plaques directly alter normal brain function
comes from electrophysiological and imaging studies showing that
Ab plaques deregulate normal neuronal firing and lead to
structural and functional disruption of neuronal networks [3,4].
Therefore, when a potential therapeutic agent is assessed in pre-
clinical studies (e.g., using mouse models), it is imperative to
consider its concomitant effects not only on soluble Ab and tau but
also on plaques and tangles.
Growing evidence highlights the role of autophagy in several
age-dependent neurodegenerative disorders characterized by
protein accumulation, including AD [5,6,7,8]. Indeed, the well-
documented decrease in autophagy function with age may
contribute to the accumulation of proteins in the brain [8,9].
Autophagy is one of the major intracellular proteolytic systems
[10]; two key steps in the autophagy system are the formation of
the autophagosomes, which are small double membrane organ-
elles that engulf organelles/proteins to be degraded, and the fusion
of the autophagosome with the lysosome, where proteins are
degraded [11,12,13]. The autophagosome formation is mediated
by ubiquitin-like reactions of a series of autophagy related proteins
(Atg) [11,12]. The key role that some Atg proteins play in
autophagy induction has been shown by knockout experiments
[14,15].
Aging is the major risk factor for the development of AD but
little is known about the interaction between aging and AD
pathogenesis. Overwhelming evidence shows that reducing the
activity of the mammalian target of rapamycin (mTOR) increases
lifespan in a variety of organisms [16,17,18,19,20,21]. Toward this
end, administration of rapamycin, an mTOR inhibitor, signifi-
cantly increased lifespan in mice [16]. mTOR is a protein kinase
that regulates protein homeostasis by facilitating protein transla-
tion and inhibiting autophagy [22]. Previous reports have shown
that mTOR is hyperactive in selected neurons in AD brains
[23,24,25,26,27], and we have directly linked mTOR hyperactiv-
ity to Ab accumulation [28]. Furthermore, we showed that
rapamycin administration increases autophagy and decreases
soluble Ab and tau in young 3xTg-AD mice [29]. However, the
concomitant effects of reducing mTOR signaling by rapamycin on
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deficits have not been addressed nor has it become clear whether
rapamycin may affect AD-like pathology in old mice. These are
critical questions to answer, especially considering that the
cognitive deficits associated with AD become significantly more
severe with the progression of the disease and the development of
plaques and tangles and that age is the major risk factor for the
development of AD.
Results
To determine the effects of rapamycin on AD-like pathology in
the 3xTg-AD mice, microencapsulated rapamycin (14 mg/kg) was
added to the chow of the following groups of mice: (i) 2-month-old
3xTg-AD and NonTg mice fed rapamycin for 16 months (herein
referred to as 3xTg-AD
2–18 and NonTg
2–18); (ii) 3xTg-AD and
NonTg mice fed the control diet until 15 months of age, after
which mice were switched to the rapamycin diet for 3 additional
months (herein referred to as 3xTg-AD
15–18 and NonTg
15–18); (iii)
3xTg-AD and NonTg mice fed the control diet throughout the
experiment (herein referred to as 3xTg-AD
CTL and NonTg
CTL)
(Fig. 1A). Overall, we used 120 mice, 20 per genotype per group;
all mice were 18 months of age at the end of treatments. Notably,
at 2 months of age, the 3xTg-AD mice do not have any apparent
neuropathological alterations or learning and memory deficits
[30,31]. In contrast, 15-month-old 3xTg-AD mice have well
established plaques and tangles throughout their brains and robust
cognitive deficits [30,31]. Thus, we are positioned to address
whether rapamycin can prevent the development of AD-like
pathology in the 3xTg-AD mice (by starting the treatment at 2
months of age) or whether it can reverse established plaques,
tangles and cognitive deficits (by starting the treatment at 15
months of age). The 3xTg-AD
15-18 mice were treated for 3 months
based on previous studies showing that in young mice 10-12 weeks
of rapamycin administration is sufficient to reduce soluble Ab and
tau [29,32]. The 3xTg-AD
2–18 mice were treated for 16 months in
order to reach the same age as the 3xTg-AD
15–18 during the
behavioral tests and the neuropathological assessments. All 6
groups of mice significantly and equally gained weight over the
treatment with no statistically significant differences observed
across genotype or treatment group (Fig 1B).
Early, but not late rapamycin administration ameliorates
learning and memory deficits
At the end of the rapamycin administration, mice from all of the
groups were 18 months of age. At this age, the 3xTg-AD mice
have robust behavioral deficits in cortical- and hippocampal-
dependent tasks [31,33]. To determine the effects of rapamycin on
learning and memory, during last 10 days of treatment, mice were
tested using two independent behavioral paradigms: the spatial
version of the Morris water maze (MWM), a hippocampal-
dependent task [34], and the object recognition task, a behavioral
task mainly dependent on multiple cortical areas, including the
perirhinal cortex [35,36].
During the MWM, mice received 4 training trials per day for 5
consecutive days to find a hidden platform. Their performance
was analyzed using a mixed-model, repeated-measures ANOVA,
with treatment and genotype as the categorically fixed effects, days
as the numeric covariate, animals as the random effect, and escape
latency as the dependent variable. We found a significant effect for
days (F=36.2; p,0.0001), indicating that the mice learned the
task across sessions (Fig. 2A). More important, we found a
significant genotype/treatment-day interaction (F=2.68;
p=0.021), indicating that one or more of the groups was different
from the others (Fig. 2A). To find which group(s) was different
from the others, we performed a post hoc test with Bonferroni
corrections and compared each of the individual groups to the
NonTg mice on the control diet. We found that the NonTg
2–18
mice performed significantly better than NonTg
CTL (p,0.05;
escape latency at day 5 was 20.761.05 seconds and 29.162.7
seconds, respectively). This is consistent with the beneficial effects
of rapamycin on mice’s health span [37]. In contrast, the escape
latency of the NonTg
15–18 mice was not statistically different from
NonTg
CTL mice (p,0.05; Fig. 2A). When we analyzed the
performance of the 3xTg-AD mice, we found that 3xTg-AD
CTL
mice performed significantly worse than NonTg
CTL mice (p,0.05;
escape latency at day 5 was 37.9662.9 and 29.162.7, respective-
ly), which is consistent with previous reports [31]. Furthermore, we
found that the 3xTg-AD
15–18 mice performed similarly to the
3xTg-AD mice on the control diet (Fig. 2A). Most notably,
however, we found that when rapamycin was administered for 16
months, starting at 2 months of age, the escape latency of the
3xTg-AD
2–18 mice was improved, as these mice performed
significantly better than the 3xTg-AD
CTL mice (p,0.05; escape
latency at day 5 was 26.962.1 and 37.962.9, respectively). In
summary, we found that rapamycin, when used prophylactically,
significantly improves spatial learning in both 3xTg-AD and
NonTg mice (Fig. 2A). In contrast, rapamycin started at 15
months of age has no significant effect on spatial learning in either
NonTg or 3xTg-AD mice.
Figure 1. Short- and long-term rapamycin treatments do not
cause overt side effects. (A) Schematic of the experimental design.
3xTg-AD and NonTg mice were randomly assigned to one of the
following groups: (i) 20 mice/genotype fed rapamycin-containing food
starting at 2 months of age for 16 months; (ii) 20 mice/genotype fed
control diet for the first 15 months of their life after which they were fed
rapamycin-containing food for 3 months; (iii) 20 mice/genotype fed
control diet throughout their life. All mice were 18 months of age at the
end of the treatment. (B) All mice gained weight throughout the
treatment and no statistically significant differences were found among
the groups. Data are presented as means 6 SEM.
doi:10.1371/journal.pone.0025416.g001
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memory by measuring the time mice spent in the target quadrant
and the number of platform location crosses over a 60-second
probe trial. One-way ANOVA indicated significant changes in the
time the mice spent in the target quadrant and the number of
platform location crosses (Fig. 2B–C; p=0.03 and p,0.0001,
respectively). A post hoc test with Bonferroni correction showed
that the NonTg
2–18 mice performed significantly better that the
NonTg
15–18 mice and the NonTg
CTL mice in both tasks (p,0.05).
Similarly, the 3xTg-AD
2–18 mice performed significantly better
than 3xTg-AD
15–18 and 3xTg-AD
CTL mice in both tasks (p,0.05;
Fig. 2B–C). Finally, this post hoc analysis also showed that the
3xTg-AD
2–18 mice performed similarly to the NonTg
CTL mice.
To determine whether mouse physical performance may account
for the changes in spatial learning and memory, we measured the
swim speed and the distance mice traveled during the probe trials.
One-way ANOVA indicated that both parameters were not
significantly different across all 6 groups of mice (Fig. 2D–E).
Taken together these findings clearly indicate that when given
prophylactically, rapamycin ameliorated spatial learning and
memory in both the NonTg and 3xTg-AD mice.
To assess cortical function, mice were also tested in object
recognition, which relies mostly on cortical areas, including the
perirhinal cortex [35,36]. This task exploits the natural tendency
of mice to explore objects perceived as novel and therefore is less
stressful than the MWM [38,39]. One-way ANOVA indicated
significant changes in the time mice spent exploring the new object
across the 6 different groups (Fig. 2F; p=0.01). To find which
group(s) was different from the others, we performed a post hoc
test with Bonferroni corrections and compared each of the
individual groups to each other. We found that the 3xTg-AD
CTL
mice performed at a chance level and significantly worse than
NonTg
CTL mice (p,0.05; Fig. 2F). Furthermore, the post hoc
analysis indicated that rapamycin did not improve recognition
memory in both groups of the rapamycin-treated NonTg mice
(Fig. 2F). Similarly, the 3xTg-AD
15–18 mice performed at a chance
level, indicating that this paradigm treatment had no effect on
recognition memory (Fig. 2F). In contrast, we found that the 3xTg-
AD
2–18 mice performed significantly better than the 3xTg-AD
CTL
mice (p,0.05; Fig. 2F), clearly indicating that rapamycin, when
given prophylactically improves recognition memory in the 3xTg-
AD mice.
Rapamycin reduces Ab plaques and neurofibrillary
tangles formation
All mice were 18 months of age when sacrificed, which was
immediately following the last behavioral testing. To determine
the effects of rapamycin on Ab pathology, we first assessed
whether rapamycin altered APP processing. Toward this end, the
levels of human brain APP and its two major C-terminal
fragments were measured by Western blot (Fig. 3A). Quantitative
analysis of the blots showed that the steady-state levels of the APP
transgene were similar across the three groups of 3xTg-AD mice,
as indicated by one-way ANOVA (p.0.05). The two major C-
terminal fragments of APP are C99 and C83, which are generated
from the cleavage of APP by a-secretase and BACE, respectively.
Western blot analysis, using an antibody against the C-terminal
region of APP, showed that neither fragments were altered by
rapamycin (Fig. 3C–D; p.0.05 as determined by one-way
ANOVA). Together these results show that APP production is
not altered by rapamycin administration.
We next determined whether plaque load was altered by
rapamycin. Toward this end, sections from 3xTg-AD
CTL, 3xTg-
AD
15–18 and 3xTg-AD
2–18 mice (n=8/group) were stained with a
widely used anti-Ab42 specific antibody [40,41,42,43]. The 3xTg-
AD
CTL mice showed a widespread Ab deposition throughout the
brain (Fig. 4A), including the hippocampus (Fig. 4B). Several of
these Ab deposits were also thioflavin S-positive (Fig. 4C),
indicating the presence of fibrillar aggregates of Ab. The Ab
pathology in the 3xTg-AD
15–18 mice was similar to the 3xTg-
AD
CTL mice, as indicated by Ab immunostaining (Fig. 4D–E) and
thioflavin (4F). In contrast, we found that Ab deposition was
reduced in the 3xTg-AD
2–18 mice (Fig. 4G–I). Semi-quantitative
analysis showed that the number of the thioflavin-positive plaques
in the 3xTg-AD
2–18 was reduced 52.36% and 55.62% compared
to 3xTg-AD
CTL and 3xTg-AD
15–18 mice, respectively (Fig. 4J).
Figure 2. Rapamycin prevents, but does not rescue learning
and memory deficits. (A) Mice were evaluated in the spatial
reference version of the MWM. Mice significantly learned the task over
the 5 days of training, as indicated by a reduced time to find the escape
platform (F=36.2; p,0.0001 as calculated by a mixed-model repeated-
measures ANOVA). There was also a significant genotype/treatment-day
interaction (F=2.68; p=0.021). Bonferroni post hoc analysis showed
that the NonTg
2–18 mice learned the task significantly quicker than the
NonTg
CTL mice. In contrast, the NonTg
15–18 mice learned as well as the
NonTg
CTL mice. Similarly, 3 months of rapamycin treatment did not
improve learning in the 3xTg-AD mice as the 3xTg-AD
15–18 mice
performed similarly to the 3xTg-AD
CTL mice. In contrast, we found that
the 3xTg-AD
2–18 mice learned the task significantly quicker than 3xTg-
AD
CTL mice and as well as NonTg
CTL mice. (B–C) Reference memory,
measured 24 hours after the last training trials was significantly
improved only in the NonTg
2–18 and 3xTg-AD
2–18 mice compared to
the NonTg
CTL and 3xTg-AD
CTL mice, respectively. Three months of
rapamycin administration, however, did not have any effect on
reference memory. (D–E) Swimming speed and distance traveled
during the probe trials were not significantly different among the 6
groups of mice. (F) Mice were also tested using the object recognition
task, a cortical-dependent task. One-way ANOVA showed significant
changes in the time mice spent exploring the new object across the 6
different groups (Fig. 2F; p=0.01). Post-hoc analysis showed that short-
and long-term rapamycin treatment had no effect on NonTg mice. In
contrast, the 3xTg-AD
2–18 mice performed significantly better than the
3xTg-AD
CTL mice. Data are presented as means 6 SEM.
doi:10.1371/journal.pone.0025416.g002
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ANOVA analysis (p,0.0001). Bonferroni’s post hoc analysis
further showed that the number of thioflavin plaques was similar
between 3xTg-AD
CTL and 3xTg-AD
15–18 (p.0.05), but both of
these groups were significantly different from 3xTg-AD
2–18
(p,0.001).
To better discriminate between changes in soluble and insoluble
Ab40 and Ab42 levels, we analyzed brain extracts from treated
and untreated 3xTg-AD mice by sandwich ELISA. Consistent
with the immunohistochemical analysis, we found that in the
3xTg-AD
2–18 mice, soluble Ab40 levels were 52.18% and 56.17%
lower compared to 3xTg-AD
CTL and 3xTg-AD
15–18 mice,
respectively (Fig. 4K). Similarly, we found that in the 3xTg-
AD
2–18 mice, soluble Ab42 levels were 38.95% and 48.2% lower
compared to 3xTg-AD
CTL and 3xTg-AD
15–18 mice, respectively
(Fig. 4K). One-way ANOVA analysis indicated that these changes
were significant (p,0.0001). Bonferroni’s post hoc analysis
indicated that soluble Ab40 and Ab42 levels were not significantly
different between 3xTg-AD
CTL and 3xTg-AD
15–18 mice (p.0.05).
In contrast, soluble Ab40 and Ab42 levels were significantly lower
in the 3xTg-AD
2–18 compared to 3xTg-AD
CTL and 3xTg-AD
15–18
mice (for Ab40, p,0.05; for Ab42, p,0.001). Consistent with the
thioflavin data, we also found that rapamycin significantly
decreased insoluble Ab40 and Ab42 in the 3xTg-AD
2–18 mice,
while it had no effects on the 3xTg-AD
15–18 mice (Fig. 4I).
Similarly to the soluble Ab levels, one-way ANOVA showed
significant changes in insoluble Ab40 and Ab42 levels across the
three groups (p,0.0001); Bonferroni’s multiple comparison test
indicated that the only group in which insoluble Ab levels were
significantly reduced was the 3xTg-AD
2–18 mice. Together, these
data show that rapamycin reduces Ab plaques formation when
administered before plaques are formed. In contrast, under the
conditions used here, rapamycin administration has no effect on
established plaque pathology. It remains to be determined whether
a longer period of rapamycin administration (e.g., from 15 to 24
months of age) may have different effects on Ab load.
In addition to Ab pathology, the 3xTg-AD mice develop age-
dependent tau pathology [30,44]. To determine the effects of
rapamycin on established neurofibrillary tangles, we stained
sections from 3xTg-AD
CTL, 3xTg-AD
15–18 and 3xTg-AD
2–18
mice (n=8/group) with two different phospho-specific anti-tau
antibodies, AT100 and AT180. The former recognizes PHF-tau
phosphorylated at Ser212 and Thr214, two amino acids selectively
phosphorylated in AD brains [45]; The latter recognizes PHF-tau
phosphorylated at Thr231 and Ser235, two amino acids that are
physiologically phosphorylated in immature and adult brains, but
are strongly hyperphosphorylated in AD brains [46]. In the brains
of the 3xTg-AD
CTL mice, we found strong immunostaining with
both AT100 and AT180 (Fig. 5A–B), which is consistent with
previous reports [31,44]. Rapamycin administration to 3xTg-
AD
15–18 mice had no effect on AT100 and AT180 immunoreac-
tivity (compare Fig. 5 A and C, and B and D). In contrast, we
found that the immunoreactivity levels of both epitopes were
significantly reduced in the 3xTg-AD
2–18 mice (Fig. 5E–F).
We next assessed changes in tau pathology using biochemical
means. Western blot analysis with a pan human specific tau
antibody showed that the steady-state levels of the tau transgene
were similar across the three different groups (Fig. 5G–H; p.0.05
as determined by one-way ANOVA). In contrast, we found that
the steady state levels of tau phosphorylated at the AT100 and
AT180 epitopes were significantly decreased by rapamycin
administration (p=0.018 for AT100 and p=0.0003 for AT180).
Bonferroni’s multiple comparison test showed that AT100 and
AT180 levels in the 3xTg-AD
2–18 mice were significantly reduced
compared to the 3xTg-AD
CTL and 3xTg-AD
15–18 mice (p,0.05
for AT100 and p,0.01 for AT180). Taken together, these data
strongly suggest that life-long rapamycin administration reduces
the accumulation of pathological tau, whereas starting rapamycin
treatment after tangles are formed has no significant effects on tau
pathology.
Rapamycin reduces microglia activation
There is some controversy as to the role of brain inflammation
in AD pathogenesis [47,48,49]. It is clear, however, that microglia
activation is an invariable feature of AD pathology [48,50].
Previous reports have shown that in the 3xTg-AD mice, activated
microglia are first detected in the CA1/subiculum region of the
hippocampus and correlate with the onset of fibrillar Ab deposits
in the same brain region [51]. To determine whether the
reduction in fibrillar Ab deposits corresponded to a decrease in
microglia activation, sections from 3xTg-AD
CTL, 3xTg-AD
15–18,
3xTg-AD
2–18 mice were stained with CD45, a common marker of
activated microglia. As expected, 18-month-old 3xTg-AD
CTL
mice showed clear CD45-positive immunoreactivity throughout
the hippocampus (Fig. 6A). When we compared sections from
3xTg-AD
CTL, 3xTg-AD
15–18, and 3xTg-AD
2–18 mice, we found
that the number of activated microglia was similar between 3xTg-
AD
CTL and 3xTg-AD
15–18 mice (Fig. 6A–B, D). In contrast, we
found that the 3xTg-AD
2–18 mice had a significantly lower
number of activated microglia compared to the other two groups
of 3xTg-AD mice (Fig. 6A–D; p=0.01 as determined by one-way
ANOVA). Bonferroni post hoc analysis confirmed that the
number of activated microglia in 3xTg-AD
2–18 mice was
significantly lower than in the 3xTg-AD
CTL and 3xTg-AD
15–18
mice. In contrast, no difference was detected between 3xTg-
Figure 3. Rapamycin does not change APP processing. (A)
Representative Western blots of proteins extracted from 3xTg-AD
CTL,
3xTg-AD
15–18 and 3xTg-AD
2–18 mice (n=8/group) and probed with the
indicated antibodies. (B–C) Quantitative analysis of the blots showed
that rapamycin did not change the steady-state levels of full length APP
or its two major C-terminal fragments, C99 and C83. Data are presented
as means 6 SEM and analyzed by one-way ANOVA.
doi:10.1371/journal.pone.0025416.g003
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CTL and 3xTg-AD
15–18 mice (Fig. 6D). These results highlight
a correlation between the reduction in fibrillar Ab deposits and the
number of activated microglia.
Rapamycin increases autophagy induction in both
3xTg-AD
15–18 and 3xTg-AD
2–18 mice
Rapamycin is a well-known mTOR inhibitor [52]. mTOR
activity is routinely assessed by measuring the steady-state levels of
downstream targets directly phosphorylated by mTOR. Along
these lines, p70S6K is a protein kinase directly phosphorylated by
mTOR at threonine 389. Indeed, a large body of evidence shows
that the levels of p70S6K phosphorylated at threonine 389
(p70S6K-Thr389) strongly and consistently correlate with mTOR
activity [53,54,55,56]. To better understand the molecular
mechanisms underlying the rapamycin-mediated decrease in Ab
and tau pathology, we first measured the steady-state levels of total
and phosphorylated p70S6K by Western blot. We found that
while the total levels of p70S6K were similar among 3xTg-AD
CTL,
3xTg-AD
15–18, 3xTg-AD
2–18 mice (Fig. 7A–B), the levels of
p70S6K-Thr389 were significantly decreased in the two rapamy-
cin-treated groups (Fig. 7A, C; p,0.0001 as assessed by one-way
ANOVA). Bonferroni’s post hoc analysis indicated the 3xTg-
AD
15–18 and the 3xTg-AD
2–18 mice were both significantly
different from 3xTg-AD
CTL (p,0.001), but not from each other
(Fig. 7C). These data indicate that mTOR signaling is decreased in
the brain of rapamycin-treated 3xTg-AD mice and are consistent
with previous reports showing that rapamycin does cross the blood
brain barrier [52,57,58,59,60].
mTOR is a negative regulator of autophagy induction, which is
one of the two major catabolic processes utilized by cells for
protein turnover [61,62,63]. Autophagy induction occurs via the
activation of a series of autophagy related proteins (Atg), which
lead to formation of autophagosomes through a cascade of
reactions resembling the ubiquitin conjugation system [11,13,64].
Atg5 and Atg7 are two autophagy-related proteins, both of which
are necessary for autophagy induction [11,13]. We initially
measured the steady-state levels of Atg7 by Western blot in the
brains of 3xTg-AD
15–18, 3xTg-AD
2–18 and 3xTg-AD
CTL mice
(Fig. 7A, D). One-way ANOVA showed a significant difference in
Atg7 levels between the three groups of mice (F=46.92; p,0.001).
Figure 4. Life-long rapamycin administration reduces Ab levels and deposition. (A–I) Representative sections from brains of 3xTg-AD
CTL,
3xTg-AD
15–18 and 3xTg-AD
2–18 mice (n=8/group) immunostained with an Ab-specific antibody (A–B, D–E, G–H) and stained with thioflavin S (C, F, I),
clearly show that the 3xTg-AD
2–18 mice have less diffuse and fibrillar Ab deposits compared to 3xTg-AD
CTL and 3xTg-AD
15–18 mice. (J) Semi-
quantitative assessment of the number of thioflavin-positive plaques shows no significant change between 3xTg-AD
CTL and 3xTg-AD
15–18 mice. In
contrast, the 3xTg-AD
2–18 mice have significantly less plaques compared to the other two groups. One-way ANOVA across the three different groups
shows that the changes were highly significant (F=69.65; p,0.0001). Panels B, E and H represent high magnification views of panels A, D and G. (K–
L) Soluble (K) and insoluble (L) Ab40 and Ab42 levels were measured by sandwich ELISA. Consistent with the histological results, compared to 3xTg-
AD
CTL mice, soluble and insoluble Ab40 and Ab42 levels were significantly reduced only in the 3xTg-AD
2–18 mice (F=40.50; p,0.0001 for the soluble
Ab levels; F=22.51 and p,0.0001 for the insoluble Ab levels). Data are presented as means 6 SEM.
doi:10.1371/journal.pone.0025416.g004
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significantly higher in the brains of 3xTg-AD
15–18 and 3xTg-AD
2–
18 compared to 3xTg-AD
CTL mice (p,0.01), but were not
statistically different between 3xTg-AD
15–18 and 3xTg-AD
2–18
mice (Fig. 7A, D). Atg7 facilitates the assembly of Atg5 and Atg12,
which are targeted to autophagosome vesicles [11,13]. To
determine whether the rapamycin-induced increase in Atg7 led
to an increase in the Atg5/Atg12 complex, brains from 3xTg-
AD
15–18, 3xTg-AD
2–18 and 3xTg-AD
CTL mice were analyzed by
Western blot using an Atg5-specific antibody. Mirroring Atg7
levels, the levels of Atg5/Atg12 were significantly higher in the
3xTg-AD
15–18 and 3xTg-AD
2–18 compared to 3xTg-AD
CTL mice
(Fig. 7A, E; F=64.37; p,0.001 as calculated with one-way
ANOVA and Bonferroni’s post hoc test). Notably, the levels of
Atg5/Atg12 were similar between 3xTg-AD
15–18 and 3xTg-AD
2–
18 mice (Fig. 7A, E). These data show a rapamycin-mediated
increase in autophagy induction, which was further confirmed by
measuring the levels of LC3I and II. LC3I is an autophagy-related
protein that is post-translationally modified to form LC3II during
autophagy induction; LC3II is then incorporated into the
membrane of the growing autophagosome [64]. Indeed, LC3II
levels are routinely used to assess the levels of autophagy induction
[65]. We found that while the levels of LC3I were similar among
3xTg-AD
CTL, 3xTg-AD
15–18, 3xTg-AD
2–18 mice (Fig. 7A, F), the
levels of LC3II were significantly increased in the two rapamycin-
treated groups (Fig. 7A, G; p=0.0001 as assessed by one-way
ANOVA). Bonferroni’s post hoc analysis indicated that both the
3xTg-AD
15–18 and the 3xTg-AD
2–18 mice were significantly
different from the 3xTg-AD
CTL mice (p,0.001) but not from
each other.
Taken together, the data presented here suggest that short- and
long-term rapamycin administration induce autophagy. Addition-
Figure 5. Tau pathology is significantly reduced in 3xTg-AD
2–18 mice. (A–F) Representative sections depicting CA1 pyramidal neurons from
brains of 3xTg-AD
CTL, 3xTg-AD
15–18 and 3xTg-AD
2–18 mice (n=8/group) immunostained with the indicated anti-tau antibodies. Note the reduction of
AT100- and AT180-positive neurons in the 3xTg-AD
2–18 mice compared to 3xTg-AD
CTL and 3xTg-AD
15–18 mice. (G) Representative Western blots of
proteins extracted from 3xTg-AD
CTL, 3xTg-AD
15–18 and 3xTg-AD
2–18 mice (n=8/group) and probed with the indicated antibodies. (H) Quantitative
analysis of the blots shows that rapamycin did not change the steady-state levels of full length tau transgene as measured by the human-specific
anti-tau antibody, HT7. In contrast, the levels of tau phosphorylated at the AT100 and AT180 epitopes were significantly reduced in the 3xTg-AD
2–18
mice compared to the 3xTg-AD
CTL and 3xTg-AD
15–18 mice (F=5.271 and p=0.018 for AT100; F=14.25 and p=0.0003 for AT180). Data are presented
as means 6 SEM.
doi:10.1371/journal.pone.0025416.g005
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induction and Ab clearance. Indeed, while the levels of autophagy
induction were similar between 3xTg-AD
15–18 and 3xTg-AD
2–18
mice, only the 3xTg-AD
2–18 mice showed a significant reduction
in Ab pathology compared to the 3xTg-AD
CTL mice. To start
elucidating the basis of this dissociation, we conducted electron
microscope studies using 15-month-old 3xTg-AD mice, the age at
which the 3 months of rapamycin treatment began. We found
Figure 6. Rapamycin reduced the number of activated microglia. (A–C) Representative sections from CA1/subiculum regions of brains from
3xTg-AD
CTL, 3xTg-AD
15–18 and 3xTg-AD
2–18 mice brains (n=8/group) immunostained with an anti-CD45 antibody. (D) Semi-quantitative analysis
showed that the number of activated microglia was significantly different across the three groups as determined by one-way ANOVA (F=5.7;
p=0.01). Bonferroni’s post hoc analysis showed that the number of activated microglia was significantly lower in the 3xTg-AD
2–18 mice compared to
the other two groups. No statistically significant changes were found between 3xTg-AD
CTL and 3xTg-AD
15–18 mice. Data are presented as means 6
SEM.
doi:10.1371/journal.pone.0025416.g006
Figure 7. Autophagy is equally induced in 3xTg-AD
2–18 and 3xTg-AD
15–18 mice. (A) Representative Western blots of proteins extracted
from 3xTg-AD
CTL, 3xTg-AD
15–18 and 3xTg-AD
2–18 mice (n=8/group) and probed with the indicated antibodies. (B–C) Quantitative analysis of the
blots showed that rapamycin did not change the steady-state levels of total p70S6K. In contrast, the levels of p70S6K phosphorylated at Thr389 (a site
directly phosphorylated by mTOR) were significantly changed by rapamycin administration (F=23.07; p,0.001). Bonferroni’s post hoc analysis
showed that the levels of p70S6K phosphorylated at Thr389 were not significantly different between 3xTg-AD
2–18 and 3xTg-AD
15–18 mice. In contrast,
phospho-p70S6K levels in both groups were significantly lower compared to the 3xTg-AD
CTL mice (p,0.001). (D–E) Similar results were obtained
when we quantified the levels of the autophagy-related proteins, Atg7 and Atg5/Atg12. One-way ANOVA showed that there was a group effect for
Atg7 (F=46.92; p,0.0001) and Atg5/Atg12 (F=64.37; p,0.0001). Post-hoc analysis confirmed that the levels of Atg7 and Atg5/Atg12 were
significantly higher in 3xTg-AD
15–18 and 3xTg-AD
2–18 mice compared to 3xTg-AD
CTL mice, but no significant differences were found between 3xTg-
AD
15–18 and 3xTg-AD
2–18 mice. (F–G) Quantitation of the LC3I/II levels showed that while rapamycin did not alter LC3I levels (F=2.039; p=0.1552, as
calculated by one-way ANOVA), a significant group effect was found for LC3II levels (F=14.58; p=0.0001). Consistent with the Atg levels, the groups
responsible for this difference were the 3xTg-AD
15–18 and 3xTg-AD
2–18 mice, which showed significantly higher LC3II levels compared to 3xTg-AD
CTL
mice, as determined by Bonferroni’s post-hoc test (p,0.001). The levels of LC3II were not significantly different between the 3xTg-AD
15–18 and 3xTg-
AD
2–18 mice. Data are presented as means 6 SEM.
doi:10.1371/journal.pone.0025416.g007
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tron-dense material (Fig. 8), highlighting the fact that in the 3xTg-
AD
15–18 mice, rapamycin treatment was started following the
accumulation of insoluble, electron-dense aggregates. It is
tempting to speculate that the electron-dense material represents
irreversible aggregates, perhaps too large to be engulfed by
autophagosomes or not recognized as material to be targeted for
autophagic degradation. Further studies are necessary to deter-
mine why this electron-dense material is not sensitive to autophagy
induction. Overall, our data show that under the conditions used
here, facilitating autophagy induction prophylactically has bene-
ficial effects on AD-like pathology; however, once plaques and
tangles are well established, increasing autophagy induction is not
sufficient to rescue AD-like pathology and the associated cognitive
deficits.
Discussion
Plaques and tangles are the two hallmark lesions of AD.
Recently, more attention has been focused on soluble Ab and tau
as strong evidence shows that the build-up of these two species
plays a critical role in AD pathogenesis [66,67]. That is not to say,
however, that mature plaques and tangles do not contribute to the
cognitive deficits associated with AD. In fact, elegant electrophys-
iological and imaging studies show that plaques directly alter
calcium signaling and physiological neuronal firing, as well as
cause structural alterations in the brains of AD transgenic mice
[3,4]. Thus, when evaluating a possible therapeutic compound, it
is critical to assess its effects not only on soluble Ab and tau but on
mature plaques and tangles as well. We, and others, have
previously shown that rapamycin reduces soluble Ab and tau
pathology and the associated early cognitive deficits in 6-month-
old transgenic mice [29,32]. Here we significantly extend our
previous findings and use a pharmacological approach to increase
autophagy and determine the effects on plaques and tangles
formation and/or plaques and tangles degradation. We found that
only when administered prophylactically, throughout life, does
rapamycin increase autophagy induction and reduce the forma-
tion of plaques and tangles, likely by increasing soluble Ab and tau
turnover. In contrast, if rapamycin is given to 15-month-old mice,
after plaques and tangles are well-established throughout the
brain, no changes in soluble or insoluble Ab and tau levels are
detected; consequently, cognitive deficits remain unchanged.
The role of autophagy in AD is controversial. For example,
Nixon and colleagues have shown that in AD brains there is
accumulation of autophagosomes [68]. Additionally, they showed
that autophagosomes may be another source of Ab generation,
suggesting that interventions aimed at further increasing autoph-
agy induction in AD may actually exacerbate the Ab pathology
[69]. In contrast, Wyss-Coray and colleagues have shown that
increasing autophagy induction decreases Ab pathology in an
animal model of AD [70]. Data in apparent contradiction to each
other have been also reported by others [5,29,32,71,72,73,74,75].
Our data are compatible with both views as we show that
increasing autophagy induction prior to the development of AD-
like pathology in the 3xTg-AD mice reduces the levels of soluble
Ab and tau and the formation of thioflavin-positive plaques. In
contrast, we show that if autophagy is induced after mature
plaques and tangles are formed, no changes in Ab, tau or cognitive
deficits are detected. We suggest that increasing autophagy
induction may be a valid therapeutic strategy for AD if the
intervention occurs early in the development of the disease. In
contrast, once the neuropathology is well-established, increasing
autophagy induction alone may not be sufficient to ameliorate the
neuropathological phenotype and different approaches should be
considered. Toward this end, recently it has been shown that
reversing autophagy dysfunction by increasing lysosomal function,
is a good strategy in AD [76].
Rapamycin is a product of the bacterium Streptomyces hygro-
scopicus, first discovered in soil from Easter Island [77]. It is
currently used in the clinic as an immunosuppressant to prevent
organ rejection during transplant [78]. Additionally, because of its
anti-proliferative properties, rapamycin is also being used in
clinical trials for cancer treatment [79]. In aging and age-related
disorders, rapamycin has been shown to increase lifespan and
healthspan in mice [16]. Additionally, a recent report showed that
rapamycin reverses the cellular phenotype associated with
Hutchinson-Gilford progeria syndrome, a lethal genetic disorder
characterized by premature aging [80]. Here we show that life-
long rapamycin treatment has no overt negative consequences on
health; indeed, mice on rapamycin gain weight at the same pace as
mice on the control diet. Notably, we also show that rapamycin
acts directly on brain mTOR signaling, clearly suggesting that
rapamycin crosses the blood-brain barrier. This is consistent with
previous reports showing that rapamycin crosses the blood brain
barrier in humans and various experimental models
[52,57,58,59,60]. Specifically, Cloughesy and colleagues directly
measured rapamycin levels in brain tumors extracted from
patients affected by neuroblastoma after one week of daily
rapamycin administration and showed that rapamycin was present
in the brain tissue, clearly indicating that rapamycin crossed the
blood-brain barrier [57].
We have previously shown that in the 3xTg-AD mice tau
pathology is highly dependent on Ab accumulation [31,81,82,83].
Figure 8. Abnormal autophagosomes in 15-month-old 3xTg-
AD mice. Electron microscope sections obtained from CA1 regions of
15-month-old 3xTg-AD mice. Sections show examples of enlarged
autophagosomes containing electron-dense undigested materials. Top-
left panel: N=nucleus; the arrowhead points to the nuclear membrane;
the arrows point to enlarged autophagosomes. Top-right panel: the
arrowhead points to an autophagosome that does not contain
undigested material. The arrow points to an autophagosome contain-
ing undigested material. Similar structures are also shown in the
bottom two panels (arrows).
doi:10.1371/journal.pone.0025416.g008
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anti-Ab antibodies were sufficient to reduce tau pathology [81].
Additionally, we showed that genetically preventing Ab accumu-
lation was sufficient to greatly delay tau accumulation, even
though the tau transgene levels remained unaltered [31]. Here we
show that rapamycin reduces the hyperactive mTOR signaling in
the 3xTg-AD mice and decreases Ab and tau pathology. However,
it remains to be established whether the changes in tau pathology
are directly due to an interaction between mTOR signaling and
tau or are simply due to a decrease in Ab pathology. Indeed, a link
between tau and mTOR has been proposed by different
laboratories. For example, PI3K/mTOR signaling regulates tau
phosphorylation [84] and TOR activation enhances tau-induced
neurodegeneration in a Drosophila model of tauopathies [85].
Further strengthening the mTOR/tau link is the data from studies
of AD brains showing that mTOR signaling is selectively increased
in neurons predicted to develop NFTs and that such an increase
correlates with tau phosphorylation [23,27,86,87]. This evidence
has led to the hypothesis that the chronic increase in mTOR
function that take place during aging may facilitate the
development of tau pathology [86]. Further studies are necessary
to assess whether the rapamycin-mediated effects on tau pathology
are due to a direct link between tau and mTOR or are due
indirectly to a decrease in Ab levels.
In conclusion, pharmacologically increasing autophagy may be
a valid therapeutic approach to prevent or treat AD and other age-
related neurodegenerative disorders characterized by the accu-
mulation of misfolded proteins [88]. Toward this end, it has been
shown that increasing autophagy by rapamycin administration
decreases alpha-synuclein- and huntingtin-related neuropatholo-
gies in animal models of Parkinson and Huntington diseases,
respectively [89,90]. Finally, considering the role of aging in AD
[91], in theory, agents capable of delaying aging should also have
beneficial effects on AD phenotype. Because of its anti-aging
properties and its effects on clearing protein deposits, rapamycin
should be considered in future clinical trials for age-dependent
neurodegenerative disorders.
Materials and Methods
Mice and rapamycin administration
The mice used in these studies have been previously described
[30]. Both 3xTg-AD and NonTg mice used in these studies were
on a mixed C57BL6/129svj background. Microencapsulated
rapamycin was added at a concentration of 14 mg/kg to mouse
chow, as described previously [16]. Food containing empty
microcapsules, i.e., the microencapsulation material without the
drug, was used as the control diet. During the treatment, mice
were given ad libitum access to water and the rapamycin or control
diet. Body weight was measured before the beginning of the
treatment and monthly thereafter. All animal procedures were
approved by The Institutional Animal Care and Use Committee
of The University of Texas Health Science Center at San Antonio;
Animal protocol number 11071x, approved on June 27, 2011.
Behavioral tests
Morris water maze tests were conducted in a circular tank of 1.5
meters in diameter, located in a room with several extra maze cues
as described previously [92]. Briefly, the platform (14 cm in
diameter) location was kept constant for each mouse during
training and was 1.5 cm beneath the surface of the water, which
was maintained at 25uC throughout the duration of the testing.
Mice received 4 trials a day and were alternated among 4
pseudorandom starting points for 5 consecutive days. If a mouse
failed to find the platform within 60 seconds, it was guided to the
platform by the researcher and kept there for 20 seconds. The
inter-trial interval was 25 sec, during which time each mouse was
returned to its home cage. Probe trials were conducted 24 hours
after the last training trial. During the probe trials, the platform
was removed and mice were free to swim in the tank for 60
seconds. The training and probe trials were recorded by a video
camera mounted on the ceiling, and data were analyzed using the
EthoVisioXT tracking system.
The object recognition test was conducted in a clear Plexiglas
box (40640 cm) and was recorded with a video camera mounted
above the testing box. Mice were left free to explore two objects for
5 minutes in the same arena used for open-field activity. After a
10-minute delay, where the mice were returned to the home cage,
the mice were returned to the arena where one of the two objects
was replaced with a new object. The percentage of time spent
exploring the new object was measured with EthoVision.
Protein extraction, Western blot, and ELISA
Mice were sacrificed by CO2 asphyxiation and their brains
extracted and cut in-half sagittally. For immunohistochemical
analysis, one-half of the brain was dropped-fixed in 4%
paraformaldehyde in PBS for 48 hours and then transferred in
0.02% sodium azide in PBS until slicing. The other half was frozen
in dry ice for biochemical analysis. Frozen brains were
homogenized in a solution of tissue protein extraction reagent
(T-PER, Pierce, Rockford, IL) containing 0.7 mg/ml Pepstatin A
supplemented with a complete Mini protease inhibitor tablet
(Roche, Switzerland) and phosphatase inhibitors (Invitrogen,
Carlsbad, CA). The homogenized mixes were briefly sonicated
to sheer the DNA and centrifuged at 4uC for 1 hour at 100,000 g.
The supernatant was stored as the soluble fraction. The pellet was
re-homogenized in 70% formic acid and centrifuged as above.
The supernatant was stored as the insoluble fraction.
For Western blot analyses as described in [93], proteins from
the soluble fraction were resolved by 10% Bis-Tris SDS/PAGE
(Invitrogen, Carlsbad, CA) under reducing conditions and
transferred to a nitrocellulose membrane. The membrane was
incubated in a 5% solution of non-fat milk for 1 hour at 20uC.
After overnight incubation at 4uC with primary antibody, the blots
were washed in Tween 20-TBS (T-TBS) (0.02% Tween 20,
100 mM Tris pH 7.5; 150 nM NaCl) for 20 minutes and
incubated at 20uC with secondary antibody. The blots were
washed in T-TBS for 20 minutes and incubated for 5 minutes with
Super Signal (Pierce, Rockford, IL), washed again and exposed.
Ab40 and Ab42 levels were measured from the soluble and
insoluble fractions using a sandwich ELISA protocol as described
in [94].
Immunohistochemistry
For immunohistochemical analysis, 50 mm thick sections were
obtained using a Leica vibratome slicing system and sections were
stored at 4uC in 0.02% sodium azide in PBS. To quench the
endogenous peroxidase activity, free-floating sections were incu-
bated for 30 minutes in H2O2. For the Ab staining, sections were
subsequently incubated in 90% formic acid for 7 minutes to
expose the epitope. The appropriate primary antibody was applied
and sections were incubated overnight at 4uC. After removing the
primary antibody in excess, sections were incubated in the
appropriate secondary antibody for 1 hour at 20uC. After a final
wash of 20 minutes, sections were developed with diaminobenzi-
dine (DAB) substrate using the avidin-biotin horseradish peroxi-
dase system (Vector Labs, Burlingame, CA). Images were obtained
with a digital Zeiss camera and analyzed with ImageJ software.
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These experiments were conducted in the Pathology Electron
Microscopy Facility of the University of Texas Health Science
Center at San Antonio using standard techniques as described
previously [44].
Statistical analyses
Statistical analyses used here were detailed in [95]. Briefly, tests
were conducted using multifactor analysis of variance, following by
the Bonferoni’s multiple comparison test to determine individual
difference among groups. Calculations were performed using
GraphPad Prism version 3.00 for Windows, GraphPad Software,
San Diego California USA, www.graphpad.com.
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